Namenda
(Memantine)ApprovedSmall molecule
AbbVieMemantine is used to treat moderate to severe Alzheimer's disease by helping to slow down memory loss and confusion. It works by regulating glutamate, a chemical in the brain involved in learning and memory.[2] Namenda is currently approved and in use across 47 indications[4].[1]
Namenda is one of 669 small molecule programs targeting Neurodegenerative Disease. It is currently in Approved.
47
Indications
167
Total Trials
19
Active Trials
668
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 45 indications
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Zolymbus
AbbViePreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Spravato
WWim Janssens
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease14 trials
Show 11 more trials
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
Completed·—·Phase 4·NCT00476008·60 enrolled
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
Completed·—·Phase 4·NCT01921972·232 enrolled
Schizophrenia8 trials
Show 5 more trials
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
Terminated·—·Phase 3·NCT00148590·24 enrolled
Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
Terminated·—·Phase 3·NCT00148616·13 enrolled
Cognitive impairment6 trials
Effect of Memantine on Radiotherapy-related Cognitive Impairment
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT03342443·240 enrolled
Show 3 more trials
Moderate to Severe Alzheimer's Disease5 trials
Show 2 more trials
Dementia5 trials
Show 2 more trials
88 more indications
Treatment4 trials
Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
Completed·—·N/A·NCT00928954·10 enrolled
Show 1 more trial
Memory4 trials
Amyotrophic Lateral Sclerosis4 trials
Bipolar Disorder4 trials
Agitation3 trials
Memantine for Agitation in Dementia
Completed·—·Phase 4·NCT00371059·153 enrolled
Down syndrome3 trials
Brain Injury3 trials
Autism Spectrum Disorder3 trials
Obsessive-Compulsive Disorder3 trials
Autism3 trials
Neuropathic Pain3 trials
Cognition3 trials
Parkinson's Disease3 trials
MPA2 trials
Systemic Lupus Erythematosus2 trials
Glaucoma2 trials
Post Operative Pain2 trials
Memantine and Postoperative Pain
Terminated·—·Phase 4·NCT01032759·77 enrolled
Aphasia2 trials
Whole-Brain Radiotherapy2 trials
Single Dose2 trials
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
Active, not recruiting·—·Phase 2·NCT05418049·45 enrolled
Multiple Sclerosis2 trials
Memantine Therapy for Multiple Sclerosis
Terminated·—·Phase 2·NCT00638833·20 enrolled
Brain Metastases2 trials
Neurodegenerative Disease1 trial
Monotherapy1 trial
Migraine1 trial
Brain Metastases From Solid Tumors1 trial
Cognitive Functions1 trial
AIN1 trial
Rehabilitation1 trial
Post-Traumatic Stress Disorder1 trial
Bipolar Depression1 trial
Women1 trial
Acute1 trial
Fibromyalgia1 trial
Randomised Controlled Trial of Memantine in Fibromyalgia
Unknown status·—·Phase 3·NCT01653457·60 enrolled
Neurotoxicity1 trial
Psychosis1 trial
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Recruiting·—·Phase 1·NCT04789915·46 enrolled
Atrophy1 trial
Transcranial Magnetic Stimulation1 trial
Cognitive Deficit1 trial
AIDS dementia1 trial
A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000867·120 enrolled
Huntington's Disease1 trial
Study of Memantine to Treat Huntington's Disease
Completed·—·Phase 4·NCT00652457·50 enrolled
Alzheimer disease1 trial
Relapse1 trial
Frontotemporal Dementia1 trial
Cognitive Function1 trial
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
Not yet recruiting·—·Phase 2·NCT06594172·67 enrolled
Fed1 trial
Partial Epilepsy1 trial
Bulimia Nervosa1 trial
Peripheral Neuropathy1 trial
Alcohol Dependence1 trial
A Placebo-Controlled Trial of Memantine for Alcohol Dependence
Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT00246415·90 enrolled
Adult1 trial
Traumatic Brain Injury1 trial
Brain Tumor1 trial
Memory RT: Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT07470606·108 enrolled
Osteoporosis1 trial
Major Depressive Disorder (MDD)1 trial
Skin-Picking1 trial
Glioma of Brain1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Oct 16, 2003
NAMENDA
NDA NDA021487
Apr 18, 2005
NAMENDA
NDA NDA021627
Jun 21, 2010
NAMENDA XR
NDA NDA022525
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Namenda drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Memantine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Patent Landscape[6]
Patent Cliff
Mar 24, 2029
Earliest patent expiration — generic entry possible after this date